NCT04651153View on ClinicalTrials.gov

A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 14, 2020

Primary Completion Date

July 20, 2023

Study Completion Date

July 20, 2023

Conditions
Parkinson's Disease
Interventions
DRUG

UCB7853

Subjects will receive UCB7853 at pre-specified time-points.

OTHER

Placebo

Subjects will receive Placebo at pre-specified time-points.

Trial Locations (2)

Unknown

Up0092 201, Leiden

Up0092 101, London

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT04651153 - A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD) | Biotech Hunter | Biotech Hunter